
Telomere
Centromere
SAR1
SAR2
SAR3
SAR4
SAR5
SAR6
P11
P12
lambda 1-1
lambda 1-2
lambda 1-3
lambda 1-4
1.0 kb

Fig. 1A


Telomere
Centromere
PROBE k
3.0 kb E/Bg
SAR 3
SAR4
SAR-BRI
390 bp S (R=5)
830 bp S (R=5)
219 bp H (R=5)
1.14 kb R (R=47)
1.7 kb H (R=95)
488 bp H (R=5)
1.7 kb R (R=78)
1.0 kb S (R=45)(P)
= 500 bp
1.0 kb H (R=42)

Fig. 1B



SAR IFNalpha (3483 bps)

Fig. 1C



Fig. 2



Fig. 3A



Fig. 3B



Fig. 3C



Fig. 3D

pTT54 (+S/MAR)



pTT55 (-S/MAR)



Fig. 3E



Fig. 4A



Fig. 4B



Fig. 4C


dpt: days post-transfection
pool maintained under puromycin selection
Transient (6 dpt) d6 batch
Pool CHO (25 dpt) d6 batch
pTT54 pTT55 pTT54 pTT55
260
135
95
72
52
Non-reducing conditions
75
50
37
Reducing conditions
Anti-hFc (Heavy Chain)

Fig. 4D


BGHpA
CMV
Puromycin
TPL
SD
enh MLP
6000
SA
EcoRV
SV40p
1000
pTT44-EG2Fc
5000
6500 bps
EG2Fc
SAR
2000
4000
3000
ClaI
pMB1ori
pA
Ampicillin
ClaI

Fig. 5A


Master cell bank
40 mL
0
4
36
41
Regular maintenance (41 days)
Batch 1 (40 mL)
Batch 2 (1L)
cell number x 10⁶/ml
cell viability (%)
day
cell density
cell viability
Batch 1
Batch 2

Fig. 5B


cell number x10^6 / ml
cell viability (%)
density
viability
Batch 1
(cells@day 6)
Time (days)
0
1
2
3
4
5
6
7
8
10
20
30
40
50
60
70
80
90
100

Fig. 5C


cell number x10^6 / ml
cell viability (%)
density
viability
Batch 2
(cells@day 36)
Time (days)
0
1
2
3
4
5
6
7
8
10
20
30
40
50
60
70
80
90
100

Fig. 5D


1.
2.
3.
4.
5.
6.
EG2Fc
1. Standards
2. EG2Fc ctrl (100 mg/L)
3. Batch 1, day 4
4. Batch 2, day 4
5. Batch 1, day 8
6. Batch 2, day 8

Fig. 5E